From the National Institutes of Health: NIH clinical trial is testing antibody against the protein in people with HIV.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV.
The new study found that women who had more CD4+ T cells displaying high levels of alpha-4 beta-7 on their surface were more likely to become infected with HIV, and the virus damage
Toxicity and patient factors were the main reasons why women did not receive treatment recommended in guidelines.From AIDSmap, Michael Carter reports.
The majority of HIV-positive women diagnosed with gynaecological cancer do not receive treatment recommended by cancer guidelines, according to research conducted in the United States and published in AIDS. Women whose care did not match guideline standards had poorer survival compared to women who received the recommended care. Toxicity and patient factors were the main reasons why women did not receive treatment recommended in guidelines.
“To our knowledge, there is no case series de
Please sign this petition calling for GIPA to be acknowledged in HIV research findings
The partnerships forged between people living with HIV and researchers have been an essential foundation upon which the response to the HIV epidemic has grown and the time has come to reaffirm and recommit to principles of inclusion and respect in the conduct of presenting research findings that impacts on our lives.
The early years of the HIV epidemic ushered in a radically different approach to traditional medical and clinical research. Academics and activists held a shared understanding th
Hear an update of how Toronto can end HIV transmissions.
Leading Toronto researchers and clinicians invite you to a discussion of how HIV prevention tools are improving and combine to get us to zero new infections.
(Speakers: Sharmistha Mishra, Rupert Kaul, Malika Sharma, Beth Rachlis, Taylor Sicard, Isaac Bogoch, Abigail Kroch. Moderator: R. Reinhard)
When: Wednesday, February 7, 2018 6:30-8:30 PM
Where: Hart House Music Room (U. of Toronto campus)
Elevator and access ramp accessible. Light refreshments will be provided.
Please RVSP by email
From The Conversation, Dennis Altman: "Desire, behaviour and identity are distinct, and do not always overlap."
This article by Dennis Altman prevously appeared at The Conversation, here.
The rise of sexually transmissible diseases made front-page news in The Age, which tried to make sense of the rise among “gay men” and “heterosexual people”.
This illustrates the increasingly common confusion between behaviour and identity. What is involved is sexual contact, or to use the expression common in the early days of the AIDS epidemic, “the exchange of bodily fluids”. Whether people involve
“Our results show that any detectable viral load between 51 and 999 copies per ml leads to poorer treatment outcomes than successful virological suppression of less than 50 copies per ml,” write the investigators. From AIDSmap, Keith Alcorn reports.
Low-level HIV viral load, above the limit of detection, is an important warning signal for future treatment failure and World Health Organization guidelines on spotting treatment failure need to be revised to encourage greater vigilance and swifter action by healthcare providers in lower- and middle-income settings, investigators report in The Lancet Infectious Diseases.
The study, carried out by Annemarie Wensing and colleagues at the University of Utrecht in the Netherlands and University
From FS Magazine, Hadley Stewart: "Despite having consented to sex, we don’t necessarily make it clear what we’re consenting to. How able do you feel to negotiate in the bedroom?"
If, like me, you’ve never sat down and thought about the term ‘consent’, you’d be forgiven for thinking that it doesn’t really apply to you.
Often we associate the term with the law, meaning that it’s easy to think it’s something that doesn’t form part of our lives unless we’ve been the victim of a crime. A sexual assault, for instance, is often paired up with the notion of consent. So does that mean we’ve never consented to anything or used our power of consent? Probably
From NAM aidsmap, Roger Pebody reports on two studies, one using long-acting injectables as TasP and one using them as PrEP.
HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling that it eliminated a “daily reminder of living with HIV”, Deanna Kerrigan and colleagues report in PLOS One.
Similarly, HIV-negative men who took injectable cabotegravir every 12 weeks as pre-exposure prophylaxis (PrEP) felt that it was probably more convenient and easier to adhere to than dai
Research indicates alternative contraception methods may help protect women.
Washington, DC - Transitioning away from a popular contraceptive shot known as DMPA could help protect women in Sub-Saharan Africa and other high-risk regions from becoming infected with HIV, according to a research review published in the Endocrine Society’s journal Endocrine Reviews.
The predominant contraceptive in Sub-Saharan Africa is depot-medroxyprogesterone acetate (DMPA)—a birth control shot administered every three months. Human studies suggest DMPA use may raise the risk of H
From NAM AIDSmap, Roger Pebody reports on two Toronto studies that shed light on how PrEP stigma is affecting PrEP uptake.
Two new qualitative studies from Toronto shed light on how stigma affects the uptake of pre-exposure prophylaxis (PrEP) and the experience of taking it. In the first, young gay men acknowledged that they did not always use condoms but did not see themselves as the kind of ‘barebacker’ for whom they thought PrEP was intended.
“PrEP embodies the notion of bareback sex, which traditionally has been associated with negative elements, and it is quite clear that the young gay men in this re
From FS Magazine, Matthew Hodson: "It’s taken us years to get this far, let’s not waste any more time."
New data released by Public Health England showed that HIV diagnoses across the country had fallen by 18%. Confined to just gay and bisexual men, the drop was 21%; narrow it even further to just gay and bisexual men in London and it was 29%.
The message is loud and clear: Combination HIV prevention works. Increasing testing and early access to treatment, plus adding PrEP to condom use as a safer sex strategy, gives us the power to send HIV into retreat. Why has it taken us so long to get here
The report, titled The World Drug PERCEPTION Problem was released on Tuesday by the Global Commission on Drug Policy. From The Globe and Mail, Andrea Woo reports.
A naloxone anti-overdose kit is shown in Vancouver on Feb. 10, 2017. JONATHAN HAYWARD/THE CANADIAN PRESS
To read the complete article by Andrea Woo, visit The Globe and Mail, here.
Skewed perceptions of drugs and people who use them negatively affect both health and health care by feeding into harmful prohibitionist policies and sometimes directly affecting clinical care, according to a new international report that aims to counter such prejudices.
The report, titled The World Drug PERCEPTI
"I chose to do this to reinforce confidence that PrEP works even in “high risk” events.," says Jason Domino. From OutNews Global, Andy West reports.
To read the complete story by Andy West and look at some video, visit Out News Global, here.
Jason Domino had sex without a condom with a fellow star with HIV to make a point.
He knew the actor wasn’t on any anti-viral medication and had a high viral load. A viral load is a metric for how much HIV is found in someone’s blood. Jason told OutNews Global: “I knew I wouldn’t get HIV. I chose to do this to reinforce confidence that PrEP works even in “high risk” events.
“Is this a signal that they’re moving away from evidence-based policy?" From Healio, this report.
To read the complete story visit Healio, here.
The AIDS czar under former U.S. President Barack Obama worries about the consequences of the Trump administration’s recent termination of the last members of a presidential HIV/AIDS council.
“Is this a signal that they’re moving away from evidence-based policymaking? That’s what’s troubling,” Jeffrey S. Crowley, MPH, program director of infectious disease initiatives at the O’Neill Institute for National and Global Health Law
Patient input presents a chance for people living with HIV to have their voices heard by drug regulators
UPCOMING CTAC PATIENT GROUP INPUT CONSULTATIONS
CTAC is calling for people living with HIV to take part in patient consultations so that they can have their voices heard by drug regulators. The first 20 attendees who complete a survey at the end of each session will recieve a $10 gift voucher.
WEDNESDAY 10TH JANUARY 2018, 2:00-3:00 EST:
NEW HIV MEDICATION DOLUTEGRAVIR / RILPIVIRINE - REGISTER HERE.
This informative webinar, led by CTAC Policy Researcher Amanda Fletcher, will discuss the